Method and kit for detecting ESR1 gene mutation based on cfDNA
By designing specific primer pairs and probes, and combining them with blocking probes, the low sensitivity of ESR1 gene mutation detection in cfDNA was solved using real-time PCR technology. This enabled high-sensitivity detection of multiple ESR1 gene mutation sites, supporting early monitoring and treatment of breast cancer patients.
Patent Information
- Application Number
- CN202411074046.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-06
AI Technical Summary
Existing technologies are not sensitive enough to detect ESR1 gene mutations in breast cancer patients, especially in cases of low copy number in cfDNA, which complicates early detection and monitoring.
Using specific primer pairs and self-designed specific probes, combined with blocking probes, we can detect multiple mutation sites in the ESR1 gene, including E380Q, L536H, L536R, L536P, Y537C, Y537N, Y537S, and D538G, through real-time quantitative PCR, thereby improving the sensitivity and accuracy of detection.
It achieves highly sensitive detection of low copy number ESR1 gene mutations, accurately detecting 0.1% of mutations in a 20ng DNA sample, providing a basis for early monitoring of gene mutations in breast cancer patients and supporting the formulation and adjustment of clinical treatment plans.
Smart Images

Figure SMS_2 
Figure SMS_3 
Figure SMS_4
Abstract
Description
Technical Field
[0001] The present specification relates to the biomedical field, and in particular to a method and kit for detecting ESR1 gene mutation based on cfDNA. Background Art
[0002] The ESR1 (Estrogen Receptor 1) gene encodes the human estrogen receptor alpha protein (ESRα). After binding to estrogen, the protein activates a series of cyclic reactions in the cell, thereby promoting cell growth and proliferation. The activation mutation of the ESR1 gene is closely related to the occurrence and development of breast cancer. Among them, the most common mutation types of the ESR1 gene include L536H, Y537S, Y537C, Y537N and D538G. These mutations can cause the conformation of ESRα to change, allowing it to present a continuous activation state without binding to estrogen.
[0003] Breast cancer is one of the most common gynecological tumors. More than 70% of primary breast cancers are estrogen receptor (ER) positive, and many breast cancers respond to endocrine therapy in the initial stage. Although new therapies for breast cancer treatment are constantly being developed and improved, innate and acquired resistance to these drugs remains a major challenge. The tumor microenvironment is considered to be the main factor that confers innate resistance to cancer treatment, and a large proportion of patients will develop resistance when receiving systemic antiestrogens such as tamoxifen or estrogen deprivation therapies such as aromatase inhibitors (AIs). Numerous mechanisms, including activation of cell survival, cell stress, and cell signaling pathways, have been proposed as drivers of acquired resistance. Recent studies have shown that activating mutations in the estrogen receptor (ESR1) gene play an important role in driving resistance. These mutations produce endoplasmic reticulum transcriptional activity that is independent of estrogen ligands and are considered resistance mutations. Secondary resistance exists due to the heterogeneity of the tumor itself. Cancer biomarkers vary between disease types and stages of disease progression, which complicates cancer detection and identification at early stages. “Liquid biopsy” approaches targeting circulating tumor DNA (ctDNA) from cell-free DNA (cfDNA) are gaining prominence for detecting and monitoring resistance to systemic therapies. Acquired resistance to hormonal therapy may be based on activating mutations in the estrogen receptor gene (ESR1). In vitro and preclinical data suggest that ESR1 mutations lead to complete resistance to AIs and partial resistance to ER agonists and antagonists. Detection of ESR1 activating mutations may be relevant to guide clinicians in endocrine and non-endocrine therapies. cfDNA fragments are relatively small, with a peak size of approximately 180 bp. The percentage of the tumor-derived ctDNA fraction in the total cfDNA is individually variable and often too low to be detected.
[0004] Therefore, it is desirable to provide a cfDNA-based ESR1 mutation detection method with high sensitivity. Summary of the invention
[0005] One or more embodiments of the present specification provide a method for detecting ESR1 gene mutation based on cfDNA, the method comprising: (1) obtaining a biological sample of a subject and extracting a cfDNA sample therefrom; (2) taking out two equal amounts of cfDNA samples from the cfDNA sample, adding them to a first container and a second container respectively for PCR amplification to detect whether the ESR1 gene in the biological sample is mutated; wherein the first container comprises a primer pair specific to E380Q of the ESR1 gene, whose sequence is shown in SEQ ID NO:76 and SEQ ID NO:83, a primer pair specific to Y537C of the ESR1 gene, whose sequence is shown in SEQ ID NO:66 and SEQ ID NO:82, a primer pair specific to Y537N of the ESR1 gene, whose sequence is shown in SEQ ID NO:34 and SEQ ID NO:82, and a primer pair specific to Y537S of the ESR1 gene, whose sequence is shown in SEQ ID NO:23 and SEQ ID NO:82; the second container comprises a primer pair specific to L536H of the ESR1 gene, whose sequence is shown in SEQ ID NO: The primer pair specific to ESR1 gene L536R is shown in SEQ ID NO:45 and SEQ ID NO:82, and its sequence is shown in SEQ ID NO:57 and SEQ ID NO:82; the primer pair specific to ESR1 gene L536P is shown in SEQ ID NO:19 and SEQ ID NO:82; and the primer pair specific to ESR1 gene D538G is shown in SEQ ID NO:10 and SEQ ID NO:82.
[0006] In some embodiments, the first container and the second container also include specific probes, internal reference probes and internal reference primers that can specifically bind to different sequences of the ESR1 gene, the sequences of the specific probes are shown in SEQ ID NO:85 and SEQ ID NO:86, the two ends of the specific probes are respectively provided with a fluorescent group and a fluorescent quenching group, the sequence of the internal reference probes is shown in SEQ ID NO:87, and the sequences of the internal reference primers are shown in SEQ ID NO:81 and SEQ ID NO:84.
[0007] In some embodiments, the first container and the second container further include a blocking probe having a sequence as shown in SEQ ID NO: 88, and the blocking probe is used to specifically bind to the non-mutated template in the sample to reduce the probability of the primer binding to the non-mutated template.
[0008] In some embodiments, the first container and the second container also include a probe of the wild sequence of ESR1 as shown in SEQ ID NO:91 and a primer of the wild sequence of ESR1 as shown in SEQ ID NO:92 and SEQ ID NO:93, and the probe and primer of the wild sequence are used to estimate the mutation frequency range of ESR1 in the sample.
[0009] In some embodiments, the loading amount of the cfDNA sample is 20 ng.
[0010] In some embodiments, the optimal concentration of the primer pair is 600 nM.
[0011] In some embodiments, the optimal concentration of the specific probe is 300 nM, and the optimal concentration of the blocking probe is 100 nM.
[0012] One or more embodiments of the present specification also provide a kit for detecting ESR1 gene mutation based on cfDNA, the kit comprising a first container and a second container; the first container comprises a primer pair specific to ESR1 gene E380Q, whose sequence is shown in SEQ ID NO:76 and SEQ ID NO:83, a primer pair specific to ESR1 gene Y537C, whose sequence is shown in SEQ ID NO:66 and SEQ ID NO:82, a primer pair specific to ESR1 gene Y537N, whose sequence is shown in SEQ ID NO:34 and SEQ ID NO:82, and a primer pair specific to ESR1 gene Y537S, whose sequence is shown in SEQ ID NO:23 and SEQ ID NO:82; the second container comprises a primer pair specific to ESR1 gene L536H, whose sequence is shown in SEQ ID NO:45 and SEQ ID NO:82, and a primer pair specific to ESR1 gene L536R, whose sequence is shown in SEQ ID NO:57 and SEQ ID NO:82. NO:82, a primer pair specific to ESR1 gene L536P, whose sequences are shown in SEQ ID NO:19 and SEQ ID NO:82, and a primer pair specific to ESR1 gene D538G, whose sequences are shown in SEQ ID NO:10 and SEQ ID NO:82; the first container and the second container also include a specific probe that can specifically bind to different sequences of the ESR1 gene, an internal reference probe and an internal reference primer, the sequence of the specific probe is shown in SEQ ID NO:85 and SEQ ID NO:86, the two ends of the specific probe are respectively provided with a fluorescent group and a fluorescent quenching group, the sequence of the internal reference probe is shown in SEQ ID NO:87, and the sequence of the internal reference primer is shown in SEQ ID NO:81 and SEQ ID NO:84.
[0013] In some embodiments, the first container and the second container further include a blocking probe having a sequence as shown in SEQ ID NO: 88, and the blocking probe is used to specifically bind to the non-mutated template in the sample to reduce the probability of the primer binding to the non-mutated template.
[0014] In some embodiments, the first container and the second container also include a probe of the wild sequence of ESR1 as shown in SEQ ID NO:91 and a primer of the wild sequence of ESR1 as shown in SEQ ID NO:92 and SEQ ID NO:93, and the probe and primer of the wild sequence are used to estimate the mutation frequency range of ESR1 in the sample.
[0015] In some embodiments, the starting amount of cfDNA sample detected using the kit is 20 ng.
[0016] In some embodiments, the concentration of the primer pair is 600 nM, the concentration of the specific probe is 300 nM, and the concentration of the blocking probe is 100 nM. DETAILED DESCRIPTION
[0017] As shown in this specification and claims, unless the context clearly indicates an exception, the words "a", "an", "an" and / or "the" do not refer to the singular and may also include the plural. Generally speaking, the terms "comprise" and "include" only indicate the inclusion of the steps and elements that have been clearly identified, and these steps and elements do not constitute an exclusive list. The method or device may also include other steps or elements. the term
[0018] The terms "about" and "around" may describe a range of values within a certain value, such as plus or minus 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the value, etc. For example, the term "about 10 mL" may include 9 mL to 11 mL.
[0019] As used herein, the terms "estrogen receptor," "ER," and "ESR1" are used interchangeably herein unless otherwise indicated. ESR1 may also be used to refer to the gene encoding the ER protein.
[0020] As used herein, the terms "nucleic acid," "polynucleotide," and "oligonucleotide" refer to polymers of nucleotides (e.g., ribonucleotides or deoxyribonucleotides), and include naturally occurring (adenosine, guanidine, cytosine, uracil, and thymidine), non-naturally occurring, and modified nucleic acids. The term is not limited by the length of the polymer (e.g., the number of monomers). Nucleic acids can be single-stranded or double-stranded, and typically contain 5'-3' phosphodiester bonds, although in some cases, nucleotide analogs may have other bonds. Monomers are often referred to as nucleotides.
[0021] The term "sample" or "biological sample" refers to any composition containing or assumed to contain nucleic acid, including tissue samples, liquid samples such as isolated cells, tissues or blood, etc. In some embodiments, the sample can be a plasma sample.
[0022] As used herein, the term "primer" refers to a short nucleic acid (oligonucleotide) that serves as a starting point for the synthesis of a polynucleotide chain achieved by a nucleic acid polymerase under suitable conditions. A primer typically includes a region of at least one target hybridization that is at least substantially complementary to the target sequence (e.g., having 0, 1, 2, or 3 mismatches). The region typically has a length of about 8 to about 40 nucleotides, e.g., 12-25 nucleotides. A "primer pair" refers to a forward and reverse primer that is oriented in opposite directions relative to the target sequence and that produces an amplification product under amplification conditions.
[0023] As used herein, the term "probe" refers to any molecule that can selectively bind to a particular intended target biomolecule (e.g., a target nucleic acid sequence that hybridizes to the probe). The probe is detectably labeled with at least one non-nucleotide portion. In some embodiments, the two ends of the probe carry a fluorescent group and a fluorescent quenching group, respectively.
[0024] As used herein, the term "container" means a container that can hold reagents or assays. If the container is in a test kit and holds reagents or is used for an amplification reaction, it can be closed or sealed to avoid contamination or evaporation. If the container is used for an assay, it can be open or accessible.
[0025] One aspect of the present specification provides a method for detecting ESR1 gene mutation based on cfDNA. The method comprises: (1) obtaining a biological sample from a subject and extracting a cfDNA sample from the biological sample.
[0026] In some embodiments, the subject can be a mammal. In some embodiments, the subject is a human.
[0027] In some embodiments, the biological sample is obtained in a non-invasive manner, for example, urine, skin, swab, saliva, blood, etc. In some embodiments, the biological sample is preferably a blood sample.
[0028] Methods for isolating DNA from biological samples are known, for example, using Roche DNA sample preparation kit, for specific operation steps, please refer to the instructions of the kit.
[0029] (2) Taking out two equal amounts of cfDNA samples from the cfDNA sample, adding them into a first container and a second container respectively for PCR amplification, and detecting whether the ESR1 gene in the biological sample is mutated. The first container comprises a primer pair specific to ESR1 gene E380Q, whose sequence is shown in SEQ ID NO: 76 and SEQ ID NO: 83, a primer pair specific to ESR1 gene Y537C, whose sequence is shown in SEQ ID NO: 66 and SEQ ID NO: 82, a primer pair specific to ESR1 gene Y537N, whose sequence is shown in SEQ ID NO: 34 and SEQ ID NO: 82, and a primer pair specific to ESR1 gene Y537S, whose sequence is shown in SEQ ID NO: 23 and SEQ ID NO: 82; the second container comprises a primer pair specific to ESR1 gene L536H, whose sequence is shown in SEQ ID NO: 45 and SEQ ID NO: 82, a primer pair specific to ESR1 gene L536R, whose sequence is shown in SEQ ID NO: 57 and SEQ ID NO: 82, and a primer pair specific to ESR1 gene L536P, whose sequence is shown in SEQ ID NO: 19 and SEQ ID NO: 10. The primer pair shown in NO:82 and specific to ESR1 gene D538G, whose sequences are shown in SEQ ID NO:10 and SEQ ID NO:82.
[0030] In some embodiments, the primer pair specific to ESR1 gene E380Q may also include: a downstream primer as shown in SEQ ID NO: 83 and any one or more upstream primers as shown in SEQ ID NO: 71-80.
[0031] In some embodiments, the primer pair specific to ESR1 gene Y537C may also include: a downstream primer as shown in SEQ ID NO: 82 and any one or more upstream primers as shown in SEQ ID NO: 61-70.
[0032] In some embodiments, the primer pair specific to ESR1 gene Y537N may also include: a downstream primer as shown in SEQ ID NO: 82 and any one or more upstream primers as shown in SEQ ID NO: 31-40.
[0033] In some embodiments, the primer pair specific to ESR1 gene Y537S may also include: a downstream primer as shown in SEQ ID NO: 82 and any one or more upstream primers as shown in SEQ ID NO: 21-30.
[0034] In some embodiments, the primer pair specific to ESR1 gene L536H may also include: a downstream primer as shown in SEQ ID NO: 82 and any one or more upstream primers as shown in SEQ ID NO: 41-50.
[0035] In some embodiments, the primer pair specific to the ESR1 gene L536R may also include: a downstream primer as shown in SEQ ID NO: 82 and any one or more upstream primers as shown in SEQ ID NO: 51-60.
[0036] In some embodiments, the primer pair specific to ESR1 gene L536P may also include: a downstream primer as shown in SEQ ID NO: 82 and any one or more upstream primers as shown in SEQ ID NO: 11-20.
[0037] In some embodiments, the primer pair specific to ESR1 gene D538G may also include: a downstream primer as shown in SEQ ID NO: 82 and any one or more upstream primers as shown in SEQ ID NO: 1-10.
[0038] In some embodiments, a 25 μl PCR reaction system is as follows:
[0039] The above PCR system is only illustrative, and in actual applications, the volume of the mixture and the content of each component therein can be proportionally increased or decreased.
[0040] In some embodiments, the PCR amplification program is 25°C, 10 min; 95°C, 5 min; (95°C, 30 s; 60°C, 60 s) 40 cycles; end.
[0041] In one embodiment, the loading amount of the cfDNA sample is about 20 ng.
[0042] In some embodiments, ESR1 gene E380Q, Y537C, Y537N, and Y537S mutation sites can be detected in the first container; and ESR1 gene L536H, L536R, L536P, and D538G mutation sites can be detected in the second container.
[0043] In some embodiments, the concentration of the primer pair can be 200 nM, 250 nM, 300 nM, 400 nM, 600 nM, 800 nM.
[0044] In some embodiments, the optimal concentration of the primer pairs is 600 nM.
[0045] In some embodiments, the first container and the second container further include a specific probe, an internal reference probe and an internal reference primer that can specifically bind to different sequences of the ESR1 gene, the sequence of the specific probe is as shown in SEQ ID NO:85 and SEQ ID NO:86, the two ends of the specific probe are respectively provided with a fluorescent group and a fluorescent quenching group, the sequence of the internal reference probe is as shown in SEQ ID NO:87, and the sequence of the internal reference primer is as shown in SEQ ID NO:81 and SEQ ID NO:84.
[0046] In some embodiments, the specific probe is an MGB-specific probe, which is linked to an MGB modifying group.
[0047] In some embodiments, the two ends of the specific probe carry a fluorescent reporter group and a fluorescent quencher group, respectively. In some embodiments, the fluorescent reporter group is selected from any one of FAM, HEX, ROX or CY5; the fluorescent quencher group is selected from any one of TAMRA, BHQ1, BHQ2 or NFQ.
[0048] In some embodiments, the fluorescent reporter group is preferably FAM; the fluorescent quencher group is preferably BHQ2.
[0049] In some embodiments, the first container and the second container also include a blocking probe having a sequence as shown in SEQ ID NO: 88, and the blocking probe is used to specifically bind to the non-mutated template in the sample to reduce the probability of the primer binding to the non-mutated template.
[0050] Since the amount of cfDNA in plasma is extremely low, the total amount of cfDNA in many samples is not high, which may result in fewer mutant sequences. In order to prevent non-specific binding of primers to wild-type templates and increase the detection of target fragments, a blocking probe is added to the original primer probe system. In the non-annealed state, the ends of the blocking probe will complement each other to form a double strand, and at the appropriate annealing temperature, the double strand will open and can specifically bind to the wild-type template, thereby reducing the possibility of primer binding to the wild-type template at the annealing temperature and improving the accuracy of the primer.
[0051] In some embodiments, the concentration of the specific probe can be 200 nM, 250 nM, and 300 nM.
[0052] In some embodiments, the concentration of the blocking probe can be 100 nm, 200 nm, 300 nm.
[0053] In some embodiments, the optimal concentration of the specific probe is 300 nM and the optimal concentration of the blocking probe is 100 nM.
[0054] In some embodiments, the first container and the second container also include probes of the wild sequence of ESR1 such as SEQ ID NO:91 and primers of the wild sequence of ESR1 such as SEQ ID NO:92 and SEQ ID NO:93, and the probes and primers of the wild sequence are used to estimate the mutation frequency range of ESR1 in the sample.
[0055] The mutation frequency can be determined by dividing the mutant template copy number by the total copy number of the mutant template and the wild-type template. In some embodiments, the probe of the ESR1 wild sequence can bind to all mutant templates and wild-type templates. The copy number of each mutant template and all templates (each mutant template and wild-type template) can be determined by the CT value. The mutation frequency range of the mutation model is obtained by dividing the copy number of the mutant template with different mutation frequencies by the total copy number of the mutant template and the wild-type template.
[0056] The method for detecting ESR1 gene mutation provided in the embodiment of this specification can detect 8 mutation sites (E380Q, L536H, L536R, L536P, Y537C, Y537N, Y537S, D538G) of the ESR1 gene based on cfDNA by fluorescence quantitative PCR (qPCR) technology. The method for detecting ESR1 gene mutation based on cfDNA effectively improves the sensitivity of its detection by adopting rationally screened upstream primers, self-designed specific probes and wild sequence probes, can accurately detect low copy mutations, and can meet the needs of clinical routine tissue sample detection.
[0057] In some embodiments, the methods are performed using a kit as described below.
[0058] Another aspect of this specification provides a kit for detecting ESR1 gene mutations based on cfDNA. In some embodiments, the kit is a kit for qPCR technology. The ESR1 gene mutation may include mutation sites such as E380Q, L536H, L536P, L536R, Y537C, Y537N, Y537S, and D538G of the ESR1 gene.
[0059] In some embodiments, the kit comprises: a first container and a second container; the first container comprises a primer pair specific to ESR1 gene E380Q, whose sequence is shown in SEQ ID NO:76 and SEQ ID NO:83, a primer pair specific to ESR1 gene Y537C, whose sequence is shown in SEQ ID NO:66 and SEQ ID NO:82, a primer pair specific to ESR1 gene Y537N, whose sequence is shown in SEQ ID NO:34 and SEQ ID NO:82, and a primer pair specific to ESR1 gene Y537S, whose sequence is shown in SEQ ID NO:23 and SEQ ID NO:82; the second container comprises a primer pair specific to ESR1 gene L536H, whose sequence is shown in SEQ ID NO:45 and SEQ ID NO:82, a primer pair specific to ESR1 gene L536R, whose sequence is shown in SEQ ID NO:57 and SEQ ID NO:82, and a primer pair specific to ESR1 gene L536P, whose sequence is shown in SEQ ID NO: NO:19 and SEQ ID NO:82, a primer pair specific to ESR1 gene D538G, whose sequences are shown in SEQ ID NO:10 and SEQ ID NO:82; the first container and the second container also include a specific probe that can specifically bind to different sequences of the ESR1 gene, an internal reference probe and an internal reference primer, the sequence of the specific probe is shown in SEQ ID NO:85 and SEQ ID NO:86, the two ends of the specific probe are respectively provided with a fluorescent group and a fluorescent quenching group, the sequence of the internal reference probe is shown in SEQ ID NO:87, and the sequence of the internal reference primer is shown in SEQ ID NO:81 and SEQ ID NO:84.
[0060] In some embodiments, the first container and the second container further include a blocking probe having a sequence as shown in SEQ ID NO: 88, and the blocking probe is used to specifically bind to the non-mutated template in the sample to reduce the probability of the primer binding to the non-mutated template.
[0061] In some embodiments, the first container and the second container also include a probe of the wild sequence of ESR1 as shown in SEQ ID NO:91 and a primer of the wild sequence of ESR1 as shown in SEQ ID NO:92 and SEQ ID NO:93, and the probe and primer of the wild sequence are used to estimate the mutation frequency range of ESR1 in the sample.
[0062] In some embodiments, the starting amount of cfDNA sample detected by the kit is 20 ng.
[0063] In some embodiments, the concentration of the primer pair is 600 nM, the concentration of the specific probe is 300 nM, and the concentration of the blocking probe is 100 nM.
[0064] In some embodiments, the kit includes a positive control solution and / or a blank control solution, wherein the positive control solution includes a mutant plasmid, and the mutant plasmid contains any one of the ESR1 gene E380Q, L536H, L536R, L536P, Y537C, Y537N, Y537S, and D538G mutant fragments.
[0065] In some embodiments, the positive control solution is a mixed solution containing 8 mutant plasmids, and the 8 mutant plasmids contain ESR1 gene E380Q, L536H, L536R, L536P, Y537C, Y537N, Y537S, D538G mutant fragments respectively. The plasmid can be a plasmid well known to those skilled in the art, and the concentrations of these 8 plasmids can be the same.
[0066] In some embodiments, the mutant plasmid concentration of the positive control solution can be 2.0×10 6 copies / μl, 2.0×10 5 copies / μl, 2.0×10 4 copies / μl or 2000copies / μl.
[0067] In some embodiments, the blank control solution includes Tris-HCl buffer.
[0068] In some embodiments, the kit further comprises a PCR buffer, an enzyme mix and / or other elements suitable for reverse transcription and amplification, such as cofactors or aptamers.
[0069] In some embodiments, the kit further includes consumables, such as plates or tubes for nucleic acid preparation, tubes for sample collection, and the like.
[0070] Another aspect of the present specification provides a primer set for detecting ESR1 gene mutation, which includes any one or more of the following primer combinations: primer combination 1, primer combination 2;
[0071] Wherein, primer combination 1 comprises: a downstream primer shown in SEQ ID NO: 83, a specific probe shown in SEQ ID NO: 86, and an upstream primer selected from any one or more of SEQ ID NOs: 21-30, SEQ ID NOs: 31-40, SEQ ID NOs: 61-70, and SEQ ID NOs: 71-80;
[0072] Primer combination 2 includes a downstream primer shown in SEQ ID NO: 82, a specific probe shown in SEQ ID NO: 85, and an upstream primer selected from any one or more of SEQ ID NOs: 1-10, SEQ ID NOs: 11-20, SEQ ID NOs: 41-50, and SEQ ID NOs: 51-60;
[0073] In some embodiments, primer combination 1 can detect E380Q, Y537C, Y537N, and Y537S mutation sites.
[0074] In some embodiments, primer combination 1-a of sequences SEQ ID NO:76, SEQ ID NO:83, and SEQ ID NO:86 can detect E380Q.
[0075] In some embodiments, primer combination 1-b of sequences SEQ ID NO:66, SEQ ID NO:82, and SEQ ID NO:85 can detect Y537C.
[0076] In some embodiments, primer combination 1-c of sequences SEQ ID NO:34, SEQ ID NO:82, and SEQ ID NO:85 can detect Y537N.
[0077] In some embodiments, primer combination 1-d of sequences SEQ ID NO:23, SEQ ID NO:82, and SEQ ID NO:85 can detect Y537S.
[0078] In some embodiments, primer combination 1 can detect L536H, L536R, L536P, and D538G mutation sites.
[0079] In some embodiments, primer combination 2-a of sequences SEQ ID NO:45, SEQ ID NO:82, and SEQ ID NO:85 can detect L536H.
[0080] In some embodiments, primer combination 2-b of sequences SEQ ID NO:57, SEQ ID NO:82, and SEQ ID NO:85 can detect L536R.
[0081] In some embodiments, primer combination 2-c of sequences SEQ ID NO: 19, SEQ ID NO: 82, and SEQ ID NO: 85 can detect L536P.
[0082] In some embodiments, primer combination 2-d of sequences SEQ ID NO: 10, SEQ ID NO: 82, and SEQ ID NO: 85 can detect D538G.
[0083] In some embodiments, the specific probes as shown in SEQ ID NO: 85 and SEQ ID NO: 86 have a fluorescent group and a fluorescent quenching group at both ends, respectively.
[0084] The above primer set can accurately detect 8 mutations of the ESR1 gene with high sensitivity and good specificity. In a 20ng DNA sample, 0.1% of mutations except for the L536H mutant template can be accurately detected.
[0085] In some embodiments, the primer set also includes an internal reference probe and an internal reference primer, the sequence of the internal reference probe is shown in SEQ ID NO:87, the sequence of the internal reference primer is shown in SEQ ID NO:81 and SEQ ID NO:84, and the internal reference probe and internal reference primer are used for sample quality assessment.
[0086] In some embodiments, the primer set further includes a blocking probe having a sequence as shown in SEQ ID NO: 88, and the blocking probe is used to specifically bind to a non-mutated template in the sample to reduce the probability of the primer binding to the non-mutated template.
[0087] In some embodiments, the primer set also includes a probe of a wild sequence of ESR1 with a sequence such as SEQ ID NO:91 and a primer of a wild sequence of ESR1 with a sequence such as SEQ ID NO:92 and SEQ ID NO:93, and the probe and primer of the wild sequence are used to estimate the mutation frequency range of ESR1 in the sample.
[0088] The present specification provides another aspect of a reagent for detecting ESR1 gene mutation, which comprises the primer set as described above.
[0089] The embodiments of the present specification provide a method, primer set, reagent and kit for detecting ESR1 gene mutation based on cfDNA, which may bring beneficial effects including but not limited to: (1) The standard substance used is prepared by using negative normal cfDNA and mutant plasmids inserted with ESR1 gene E380Q, L536H, L536R, L536P, Y537C, Y537N, Y537S, D538G mutation fragments after enzyme digestion according to different copy number ratios, which can restore the characteristics of the test sample to the greatest extent, lay the foundation for the optimization of the reaction system, and play a decisive role in the system optimization process; (2) Through the digital PCR detection of mutation frequency standards, the CT value generated by each primer binding to the template at different concentrations can be accurately detected, thereby obtaining accurate and reliable data statistics; through the digital PCR detection of wild-type templates, the background concentration of different wild-type templates in the detection system can be clearly determined. In this way, when testing samples, the interference of non-specific amplification peaks of wild sequences on the test results can be effectively avoided, making the results more accurate; by detecting low mutation frequency standards through digital PCR, the sensitivity of the detection system can be accurately determined; (3) by detecting high mutation frequency standards through fluorescent PCR, the concentration of each probe is optimized, and the appropriate primer concentration is selected according to the difference in fluorescence intensity after the reaction of primers with different concentrations of each mutation. This method has accurate results and low cost; (4) The specific probe provided in the embodiment of this specification is a self-designed MGB specific probe with a short probe sequence and good specificity. The specific probes are selected through multiple combination optimization, with high amplification efficiency and high sensitivity; (5) The probe of the ESR1 wild sequence provided in the embodiment of the present specification can be combined with the mutant template and the wild-type template. The mutation frequency range of the mutation model is obtained by dividing the copy number of the mutant template with different mutation frequencies by the total copy number of the mutant template and the wild-type template (determined according to the CT value). The method for detecting ESR1 gene mutation based on cfDNA provided in the embodiment of the present specification can provide a reference for estimating the mutation frequency of the sample; (6) The method for detecting ESR1 gene mutation based on cfDNA provided in the embodiment of the present specification is fast, efficient, and low in cost. It can detect 8 mutation sites (E380Q, L536H, L536R, L536P, Y537C, Y537N, Y537S, D538G) of the ESR1 gene based on trace cfDNA in biological samples through fluorescent quantitative PCR (qPCR) technology, and can quickly and accurately monitor whether the ESR1 gene of tumor patients has mutated, and timely monitor the patient's new gene mutation, thereby providing a strong basis for the formulation and adjustment of clinical treatment plans. Example
[0090] The experimental methods in the following Examples 1-10 are conventional methods unless otherwise specified. The experimental materials used in the following Examples 1-10 are purchased from conventional biochemical reagent companies unless otherwise specified. The quantitative tests in the following Examples 1-10 are repeated three times, and the results are averaged.
[0091] The instruments used in Examples 1-10 mainly include: vortex shaker, high-speed centrifuge, digital PCR (Xinyi Biotechnology Co., Ltd.), A300 PCR, SLAN-96s real-time PCR (Shanghai Hongshi Medical Technology Co., Ltd.) and micro-droplet preparation instrument (drop maker M1), micro-droplet sample detector (chip reader R1) (Xinyi Manufacturing Technology (Beijing) Co., Ltd.), biological safety cabinet, water bath, pipette, RainDropSense (RainDance Technologies), etc. Example 1 Primer screening
[0092] Digital PCR was used to quantitatively detect the wild-type template (wild plasmid) and mutant template (mutant plasmid) and to screen the primers.
[0093] 1. Prepare the plasmids required for the experiment
[0094] (1) Theoretically, the number of copies of a single gene per 1 ng of human DNA is about 300 copies. Dilute the concentration of wild plasmid DNA to 2.0×10 5 About copies / μl.
[0095] (2) After restriction digestion, mutant plasmids with ESR1 gene E380Q, L536H, L536R, L536P, Y537C, Y537N, Y537S, and D538G mutation fragments were obtained. The calculation formula for the mutant plasmid copy number is 9.1×10 8 × plasmid concentration (ng / μl) ÷ plasmid length (2800bp); the concentration of the obtained mutant plasmid was diluted step by step to 2.0×10 6 copies / μl, 2.0×10 5 copies / μl, 2.0×10 4 copies / μl and 2000copies / μl.
[0096] 2. Primer screening
[0097] The sequences of primers and probes for detecting ESR1 gene mutations are shown in Table 1. The specific binding degree of primers and probes to mutant templates and wild-type templates was tested respectively to screen out the optimal primers and probes for each mutation site. Table 1 Primer and probe sequences
[0098] The concentrations of the primer probes were 600 nM and 300 nM, respectively, and the concentration of the blocking probe was 100 nM. Except for the internal reference probe, all of the above-mentioned specific probes were MGB probes, and the 5' end of the probe was modified with a FAM fluorescent group.
[0099] (1) Prepare the reaction system according to the following reaction system component table, as shown in Table 2. The copy number of the mutant template is 1000 copies, and the copy number of the wild-type template is 8000 copies. Table 2 Reaction system components
[0100] (2) The PCR amplification program was 25°C, 10 min; 95°C, 5 min; (95°C, 30 s; 60°C, 60 s) for 40 cycles; end.
[0101] (3) After the above PCR reaction, the test results are shown in Tables 3-5. Among them, Table 3 is the result of digital PCR quantification of different mutant plasmids. Table 4 is the test result of using mutant templates for primers; Table 5 is the test result of using wild-type templates for primers. Table 3 Results of digital PCR quantification of different mutant plasmids Table 4 Test results of primers in mutant templates Table 5 Test results of primers in wild-type template Sample name Ct Sample name Ct Sample name Ct Sample name Ct A8F1 W 31.87 HF1 W 36.79 R1 W NoC P1 W 33.96 A8F2 W 38.12 HF2W 37.81 R2W NoC P2W 32.76 A8F3W 34.03 HF3W NoC R3W NoC P3W NoC A8F4W NoC HF4W NoC R4W NoC P4W 25.43 A8F5W 36.41 HF5W NoC R5W NoC P5W NoC A8F6 W NoC HF6W 38.40 R6W NoC P6W 38.30 A8F7W NoC HF7W NoC R7W NoC P7W NoC A8F8W 38.39 HF8W 37.33 8W 39.34 P8 35.65 A8F9 W 37.22 HF9W 37.36 9W NoC P9W NoC A8F10W 38.32 HF10W 35.35 R10 W 37.86 P10 W 34.49 CF1 W 32.18 NF1 W 37.15 S1 W NoC 3801W 34.29 CF2W 38.88 NF2W 38.56 S2W NoC 3802W 33.41 CF3W 35.05 NF3W NoC S3W NoC 3803W NoC CF4W NoC NF4W NoC S4W NoC 3804W 26.44 CF5W 38.23 NF5W NoC S5W NoC 3805W NoC CF6W NoC NF6W NoC S6W NoC 3806W NoC CF7W NoC NF7W NoC S7W NoC 3807W NoC CF8W NoC NF8W NoC 8W NoC 3808W 38.50 CF9W NoC NF9W NoC S9W NoC 3809W NoC CF10W NoC NF10W 38.88 S10 W NoC 38010W 37.93
[0102] (4) Result analysis: The optimal primers were selected based on the CT value, and the primers were screened according to the criteria that the primers produced the minimum CT value under the mutant template and did not produce a CT value under the wild-type template. The optimal primers finally determined were F536R-7, F536P-9, F536H-5, F538-10, F537C-6, F537N-4, F537S-3, and F380-6. Example 2 Primer concentration and probe concentration screening
[0103] Digital PCR was used to quantitatively detect mutant templates and screen primer concentrations.
[0104] 1. Prepare the plasmids required for the experiment
[0105] After plasmid digestion, mutant plasmids with ESR1 gene E380Q, L536H, L536R, L536P, Y537C, Y537N, Y537S, and D538G mutation fragments were obtained. The calculation formula for the mutant plasmid copy number is 9.1×10 8 × plasmid concentration (ng / μl) ÷ plasmid length (2800bp); dilute the obtained plasmid concentration step by step to 2.0×10 6 copies / μl, 2.0×10 5 copies / μl, 2.0×10 4 copies / μl, 2000copies / μl.
[0106] 2. Primer and probe concentration screening
[0107] Based on the mutant template, the specific binding degree of the primers and specific probes to the mutant template is tested respectively, and the optimal primer concentration and probe concentration for each mutation site are screened out.
[0108] (1) Prepare the reaction system according to the following reaction system component table, as shown in Table 6. The copy number of the mutant template is 1000 copies. Table 6 Reaction system components
[0109] (2) The PCR amplification program was 25°C, 10 min; 95°C, 5 min; (95°C, 30 s; 60°C, 60 s) for 40 cycles; end.
[0110] (3) When the probe concentration was set to 300 nm, the primer concentration was tested, and the primer concentrations were set to 800 nm, 600 nm and 400 nm, respectively. The results are shown in Table 7. When the primer concentration was 600 nm, the probe concentration was tested, and the probe concentrations were set to 300 nm, 250 nm and 200 nm, respectively. The detection results are shown in Table 8. Table 7 Detection results of different primer concentrations Sample name Average Ct Sample name Average Ct Sample name Average Ct Sample name Average Ct R800nM 29.21 P800nM 29.11 538800nM 31.57 H800nM 29.88 R600nM 28.82 P600nM 28.25 538600nM 30.17 H600nM 29.01 R400nM 28.91 P400nM 28.36 538400nM 30.56 H400nM 30.23 C800nM 29.40 N800nM 30.66 S800nM 31.11 380800nM 31.78 C600nM 28.03 N600nM 30.29 S600nM 30.26 380600nM 30.44 C400nM 28.33 N400nM 31.54 S400nM 30.77 380400nM 30.673 Table 8 Detection results of different probe concentrations Sample name Ct Sample name Ct Sample name Ct Sample name Ct R300nM 28.76 P300nM 28.34 538300nM 30.23 H300nM 29.12 R250nM 28.87 P250nM 28.75 538250nM 30.45 H250nM 29.61 R200nM 28.98 P200nM 29.16 538200nM 30.76 H200nM 30.63 C300nM 28.06 N300nM 30.49 S300nM 30.56 380300nM 30.24 C600nM 28.45 N600nM 30.76 S600nM 30.86 380600nM 30.54 C400nM 28.33 N400nM 31.34 S400nM 30.67 380400nM 30.97
[0111] (4) Result analysis: The optimal primer and probe concentrations were selected based on the CT values, with the primers producing the minimum CT value under the mutant template as the screening criterion. The optimal primer concentration was finally screened to be 600 nm and the optimal probe concentration was 300 nm. Example 3 Blocker probe concentration screening
[0112] Digital PCR was used to quantitatively detect the wild-type template and the mutant template, and to screen the optimal concentration of the blocker probe.
[0113] 1. Prepare the plasmids required for the experiment
[0114] (1) Dilute the concentration of wild-type plasmid DNA to about 2.0 × 10 5 copies / μl.
[0115] (2) After plasmid digestion, mutant plasmids with ESR1 gene E380Q, L536H, L536R, L536P, Y537C, Y537N, Y537S, and D538G mutation fragments were obtained. The calculation formula for the mutant plasmid copy number is 9.1×10 8 × plasmid concentration (ng / μl) ÷ plasmid length (2800bp); dilute the obtained plasmid concentration step by step to 2.0×10 6 copies / μl, 2.0×10 5 copies / μl, 2.0×10 4 copies / μl, 2000copies / μl.
[0116] 2. Screening of optimal blocker probe concentration
[0117] Based on the mutant template and the wild-type template, the specific binding degree of the blocker probe to the mutant and wild-type templates was tested to screen the optimal blocker probe concentration.
[0118] (1) According to the following reaction system component table, as shown in Table 9, the reaction system was prepared. Among them, system 1 detects the mutation sites of ESR1 gene Y537C, Y537N, Y537S and E380Q, and system 2 detects the mutation sites of ESR1 gene L536H, L536P, L536R and D538G. The copy number of mutant template is 1000 copies, and the copy number of wild-type template is 18000 copies. Table 9 Reaction system components
[0119] (2) The PCR amplification program was 25°C, 10 min; 95°C, 5 min; (95°C, 30 s; 60°C, 60 s) for 40 cycles; end.
[0120] (3) When the copy number of the wild-type template was 18000 copies, the blocker probe concentration was tested, and the blocker probe concentrations were set to 100 nm, 200 nm and 300 nm, respectively. The detection results are shown in Table 10. When the blocker probe concentration was 100 nm, the detection of each mutant template (copy number was 1000 copies) was tested, and the results are shown in Table 11. Table 10 Detection results of different concentrations of blocker probes Table 11 Detection results of 100nm blocker probe
[0121] (4) Result analysis: When the concentration of the blocker probe was 100 nM, the primer pair could block the amplification of 18,000 copies of the wild-type template, while the mutant templates could be detected normally. Example 4 Simulation sample template
[0122] Each mutant template was mixed with a wild-type template at a mutation frequency of about 13% to simulate the template extracted from a 20ng sample. Digital PCR was used to quantitatively detect the wild-type template and the mutant template.
[0123] 1. Prepare the reaction system according to the following reaction system component table, as shown in Table 12. System 1 detects the mutation sites of ESR1 gene Y537C, Y537N, Y537S and E380Q, and system 2 detects the mutation sites of ESR1 gene L536H, L536P, L536R and D538G. Table 12 Reaction system components
[0124] 2. The PCR amplification program was 25°C, 10 min; 95°C, 5 min; (95°C, 30 s; 60°C, 60 s) 40 cycles; end.
[0125] 3. After the above PCR reaction, the test results are shown in Table 13. Table 13 Test results
[0126] 4. Result analysis: When simulating a sample input of 20 ng, each mutant template can be detected normally and will not react non-specifically with the wild-type template. The primer probe in the reaction system has good specificity. Example 5 Simulating sample templates with different mutation frequencies
[0127] Each mutant template was mixed with the wild-type template at mutation frequencies of about 10%, 1%, and 0.1% to simulate the situation where templates extracted from 20 ng of sample have different mutation frequencies. Digital PCR was used to quantitatively detect the wild-type template and mutant template.
[0128] 1. Prepare the reaction system according to the following reaction system component table, as shown in Table 14. System 1 detects the mutation sites of ESR1 gene Y537C, Y537N, Y537S and E380Q, and system 2 detects the mutation sites of ESR1 gene L536H, L536P, L536R and D538G. Table 14 Reaction system components
[0129] 2. The PCR amplification program was 25°C, 10 min; 95°C, 5 min; (95°C, 30 s; 60°C, 60 s) 40 cycles; end.
[0130] 3. After the above PCR reaction, the test results are shown in Table 15. Table 15 Test results
[0131] 4. Result analysis: When simulating a sample input of 20 ng, except for the L536H mutant template, other mutant templates can be detected at a mutation frequency of 0.1%. Example 6 Estimating the mutation frequency of a sample
[0132] In order to estimate the mutation frequency range of the sample, a probe for detecting the wild-type sequence of ESR1 was designed. Digital PCR was used to quantitatively detect the mutant and wild-type templates, and the mutant templates with copy numbers of 1000 copies, 100 copies, and 10 copies were detected.
[0133] 1. Prepare the reaction system according to the following reaction system component table, as shown in Table 16. System 1 detects the mutation sites of ESR1 gene Y537C, Y537N, Y537S and E380Q, and system 2 detects the mutation sites of ESR1 gene L536H, L536P, L536R and D538G. Table 16 Reaction system components
[0134] 2. The PCR amplification program was 25°C, 10 min; 95°C, 5 min; (95°C, 30 s; 60°C, 60 s) 40 cycles; end.
[0135] 3. After the above PCR reaction, the test results are shown in Table 17. Table 17 Test results Sample name copies Ct Sample name copies Ct Sample name copies Ct E380Q-1000 ~1000 29.32 E380Q-100 ~100 32.32 E380Q-10 ~10 35.57 Y537S-1000 ~1000 32.16 Y537S-100 ~100 35.46 Y537S-10 ~10 38.86 Y537N-1000 ~1000 31.36 Y537N-100 ~100 34.06 Y537N-10 ~10 37.56 Y537C-1000 ~1000 33.61 Y537C-100 ~100 37.81 Y537C-10 ~10 39.81 D538G-1000 ~1000 34.12 D538G-100 ~100 37.02 D538G-10 ~10 39.82 L536H-1000 ~1000 34.32 L536H-100 ~100 37.42 L536H-10 ~10 39.72 L536R-1000 ~1000 29.54 L536R-100 ~100 32.26 L536R-10 ~10 35.76 L536P-1000 ~1000 31.43 L536P-100 ~100 34.39 L536P-10 ~10 37.68 ESR1 Wild ~1000 26.13 ESR1 Wild ~10000 22.83 ESR1 Wild ~5000 24.58
[0136] 4. Result analysis: The approximate number of mutation copies was selected according to the CT value. The approximate copy number was reflected by the CT value. Dividing it by the approximate copy number corresponding to the wild CT value of ESR1, the mutation frequency range of the mutation model can be obtained. Example 7 Simulation sample
[0137] DNA was extracted from gene-edited cell lines containing E380Q, L536H, L536R, L536P, Y537C, Y537N, Y537S and D538G mutations of the ESR1 gene. At the same time, cfDNA was extracted from negative plasma. After digital PCR quantification, they were mixed according to the mutation frequency of 1% to completely simulate the template extracted from the 20ng sample, and then tested using digital PCR.
[0138] 1. According to the reaction system component table shown below, as shown in Table 18, a reaction system was prepared. Among them, system 1 detects the mutation sites of ESR1 gene Y537C, Y537N, Y537S and E380Q, and system 2 detects the mutation sites of ESR1 gene L536H, L536P, L536R and D538G. Table 18 Reaction system components
[0139] 2. The PCR amplification program was 25°C, 10 min; 95°C, 5 min; (95°C, 30 s; 60°C, 60 s) 40 cycles; end.
[0140] 3. After the above PCR reaction, the test results are shown in Table 19. Table 19 Test results Sample name Mutation frequency or copies Ct E380Q - 1% 1% 33.86 Y537S - 1% 1% 36.66 Y537N-1% 1% 35.73 Y537C-1% 1% 36.81 gDNA-20ng 20ng(~6600) 26.43 D538G-1% 1% 36.42 L536H-1% 1% 36.87 L536R-1% 1% 33.23 L536P-1% 1% 35.11 gDNA-20ng 20ng(~6600) 26.62 ESR1 24.67
[0141] 4. Result analysis: The 1% mutation frequency samples simulated using cell lines and negative plasma can be detected normally. According to the results of Example 6, it can be inferred that the mutation frequency simulated this time is in the range of 1% to 2%, which verifies that the primer-probe preparation system provided in this specification has the ability to estimate the mutation frequency. Example 8 Primer-probe preparation system comparison
[0142] In order to prove the effectiveness of the primer-probe preparation system provided in this specification, a comparative experiment was conducted with the primer-probe preparation system described in the Roche patent. A negative plasma template (wild-type template, 2 ml) and a mutant plasmid (mutant template) were mixed at a ratio of 1:100 to simulate the template extracted from a 20ng plasma sample (digital PCR quantification). The specific steps are as follows:
[0143] 1. cfDNA and mutant plasmid extraction
[0144] (1) Extraction of plasma free DNA (cfDNA) using Roche DNA sample preparation kit, for specific operation steps, please refer to the instructions of the kit.
[0145] (2) Extract plasmid using a plasmid miniprep kit (D1100, Beijing Solebow Technology Co., Ltd.). For specific operation steps, please refer to the instruction manual of the kit.
[0146] 2. Determination of cfDNA and mutant plasmid concentrations
[0147] The extracted cfDNA and plasmid were quantified using QubitTM dsDNA HS Assay Kit (Q32854). The specific experimental steps were referred to the instructions of the kit.
[0148] 3. Prepare the standard products required for the experiment
[0149] (1) Plasma cfDNA was diluted step by step to about 2.0×10 5 copies / μl.
[0150] (2) After plasmid digestion, mutant plasmids with ESR1 gene E380Q, L536H, L536R, L536P, Y537C, Y537N, Y537S, and D538G mutation fragments were obtained. The calculation formula for the mutant plasmid copy number is 9.1×10 8 × plasmid concentration (ng / μl) ÷ plasmid length (2800bp); dilute the obtained plasmid step by step to 2.0×10 6 copies / μl, 2.0×10 5 copies / μl, 2.0×10 2 copies / μl and 20copies / μl.
[0151] 4. Comparison of primer and probe preparation systems
[0152] (1) According to the following reaction system component table, as shown in Tables 20-21, the PCR reaction system of this specification and the Roche PCR reaction system were prepared. Among them, system 1 detects the mutation sites of ESR1 gene Y537C, Y537N, Y537S and E380Q, and system 2 detects the mutation sites of ESR1 gene L536H, L536P, L536R and D538G. Table 20 Reaction system components Table 21 Roche PCR reaction system components
[0153] (2) The PCR amplification program was 25°C, 10 min; 95°C, 5 min; (95°C, 30 s; 60°C, 60 s) for 40 cycles; end.
[0154] (3) After the above PCR reaction, the detection results are shown in Table 22. Table 22QPCR test results
[0155] (4) Result analysis: When detecting common ESR1 gene mutations, the CT values detected under the primer-probe preparation system provided in this specification are all lower than the CT values detected under the Roche primer-probe preparation system. Therefore, the primer-probe preparation system provided in this specification is slightly better than the Roche primer-probe preparation system. In addition, this specification can be combined with the data in Example 6 to roughly estimate the mutation frequency of the sample. Example 9 Comparison with and without blocker probe
[0156] This example compares the detection results when there is a blocker probe in the primer-probe preparation system. A negative plasma template (2 ml) and a mutant plasmid were mixed at a ratio of 1:100 to simulate the template extracted from a 20 ng plasma sample; a negative plasma template (4 ml) and a mutant plasmid were mixed at a ratio of 1:100 to simulate the template extracted from a 40 ng plasma sample.
[0157] 1. Prepare the reaction system according to the following reaction system component table, as shown in Table 23. System 1 detects the mutation sites of ESR1 gene Y537C, Y537N, Y537S and E380Q, and system 2 detects the mutation sites of ESR1 gene L536H, L536P, L536R and D538G. Table 23 Reaction system components
[0158] 2. The PCR amplification program was 25°C, 10 min; 95°C, 5 min; (95°C, 30 s; 60°C, 60 s) 40 cycles; end.
[0159] 3. After the above PCR reaction, the test results are shown in Table 24. Table 24 Test results
[0160] 4. Result analysis: After adding the blocker probe, the blocker probe in the system binds to the wild template, so that the primer does not bind to the wild template to produce a CT value. In the system with the addition of the blocker probe, the binding of the primer to the wild-type template is reduced, resulting in a smaller CT value. Therefore, adding a blocker probe to the system of primer probe preparation can improve the specificity of the primer, and then the mutation frequency range of the sample can be more accurately calculated based on the data of Example 6. Example 10 Upgrading blocker probe verification
[0161] This embodiment upgrades the blocker probe.
[0162] 1. First, digital PCR was used to quantify each mutant template and wild-type template at 1000 copies / μl. Then, digital PCR was used to test the effect of adding different blocker probes (including upgraded blocker probes and ordinary blocker probes) on the CT value detection of samples.
[0163] 2. Prepare the reaction system according to the following reaction system component table, as shown in Table 25. System 1 detects the mutation sites of ESR1 gene Y537C, Y537N, Y537S and E380Q, and system 2 detects the mutation sites of ESR1 gene L536H, L536P, L536R and D538G. Table 25 Reaction system components
[0164] 3. The PCR amplification program was 25°C, 10 min; 95°C, 5 min; (95°C, 30 s; 60°C, 60 s) 40 cycles; end.
[0165] 4. After the above PCR reaction, the test results are shown in Table 26. Table 26 Test results
[0166] 5. Result analysis: When the template input amount is the same, the CT value detected by the system with the upgraded blocker probe is slightly smaller than the CT value detected by the system with the ordinary blocker probe, indicating that the upgraded blocker probe will not affect the binding of primers and templates.
[0167] The basic concepts have been described above. Obviously, for those skilled in the art, the above detailed disclosure is only for example and does not constitute a limitation of this specification. Although not explicitly stated here, those skilled in the art may make various modifications, improvements and corrections to this specification. Such modifications, improvements and corrections are suggested in this specification, so such modifications, improvements and corrections still belong to the spirit and scope of the exemplary embodiments of this specification.
[0168] At the same time, this specification uses specific words to describe the embodiments of this specification. For example, "one embodiment", "an embodiment", and / or "some embodiments" refer to a certain feature, structure or characteristic related to at least one embodiment of this specification. Therefore, it should be emphasized and noted that "one embodiment" or "an embodiment" or "an alternative embodiment" mentioned twice or more in different positions in this specification does not necessarily refer to the same embodiment. In addition, certain features, structures or characteristics in one or more embodiments of this specification can be appropriately combined.
[0169] Similarly, it should be noted that in order to simplify the description disclosed in this specification and thus help understand one or more embodiments of the invention, in the above description of the embodiments of this specification, multiple features are sometimes combined into one embodiment or its description. However, this disclosure method does not mean that the features required by the subject matter of this specification are more than the features mentioned in the claims. In fact, the features of the embodiments are less than all the features of the single embodiment disclosed above.
[0170] In some embodiments, numbers describing the number of components and attributes are used. It should be understood that such numbers used in the description of the embodiments are modified by the modifiers "about", "approximately" or "substantially" in some examples. Unless otherwise specified, "about", "approximately" or "substantially" indicate that the numbers are allowed to vary by ±20%. Accordingly, in some embodiments, the numerical parameters used in the specification and claims are approximate values, which may change according to the required features of individual embodiments. In some embodiments, the numerical parameters should take into account the specified significant digits and adopt the general method of retaining digits. Although the numerical domains and parameters used to confirm the breadth of their range in some embodiments of this specification are approximate values, in specific embodiments, the setting of such numerical values is as accurate as possible within the feasible range.
[0171] Each patent, patent application, patent application publication, and other materials, such as articles, books, specifications, publications, documents, etc., cited in this specification are hereby incorporated by reference in their entirety. Except for application history documents that are inconsistent with or conflicting with the contents of this specification, documents that limit the broadest scope of the claims of this specification (currently or later attached to this specification) are also excluded. It should be noted that if the descriptions, definitions, and / or use of terms in the materials attached to this specification are inconsistent or conflicting with the contents described in this specification, the descriptions, definitions, and / or use of terms in this specification shall prevail.
[0172] Finally, it should be understood that the embodiments described in this specification are only used to illustrate the principles of the embodiments of this specification. Other variations may also fall within the scope of this specification. Therefore, as an example and not a limitation, alternative configurations of the embodiments of this specification may be considered consistent with the teachings of this specification. Accordingly, the embodiments of this specification are not limited to the embodiments explicitly introduced and described in this specification.
Claims
1. A method for detecting ESR1 gene mutation based on cfDNA, the method comprising: (1) Obtain biological samples from subjects and extract cfDNA samples from them; (2) taking two equal amounts of cfDNA samples from the cfDNA sample, adding them to a first container and a second container respectively for PCR amplification to detect whether the ESR1 gene in the biological sample is mutated; wherein the first container includes a primer pair specific to ESR1 gene E380Q, whose sequence is shown in SEQ ID NO:76 and SEQ ID NO:83, a primer pair specific to ESR1 gene Y537C, whose sequence is shown in SEQ ID NO:66 and SEQ ID NO:82, a primer pair specific to ESR1 gene Y537N, whose sequence is shown in SEQ ID NO:34 and SEQ ID NO:82, and a primer pair specific to ESR1 gene Y537S, whose sequence is shown in SEQ ID NO:23 and SEQ ID NO:82; The second container includes a primer pair specific to ESR1 gene L536H, whose sequence is shown in SEQ ID NO:45 and SEQ ID NO:82, a primer pair specific to ESR1 gene L536R, whose sequence is shown in SEQ ID NO:57 and SEQ ID NO:82, a primer pair specific to ESR1 gene L536P, whose sequence is shown in SEQ ID NO:19 and SEQ ID NO:82, and a primer pair specific to ESR1 gene D538G, whose sequence is shown in SEQ ID NO:10 and SEQ ID NO:
82.
2. The method of claim 1, wherein: The first container and the second container also include specific probes, internal reference probes and internal reference primers that can specifically bind to different sequences of the ESR1 gene, the sequences of the specific probes are shown in SEQ ID NO:85 and SEQ ID NO:86, the two ends of the specific probes are respectively provided with a fluorescent group and a fluorescent quenching group, the sequence of the internal reference probe is shown in SEQ ID NO:87, and the sequence of the internal reference primers are shown in SEQ ID NO:81 and SEQ ID NO:
84.
3. The method of claim 1, wherein: The first container and the second container also include a blocking probe with a sequence as shown in SEQ ID NO: 88, and the blocking probe is used to specifically bind to the non-mutated template in the sample to reduce the probability of the primer binding to the non-mutated template.
4. The method of claim 1, wherein: The first container and the second container also include a probe of the wild sequence of ESR1 as shown in SEQ ID NO:91 and primers of the wild sequence of ESR1 as shown in SEQ ID NO:92 and SEQ ID NO:93, and the probe and primers of the wild sequence are used to estimate the mutation frequency range of ESR1 in the sample.
5. The method of claim 1, wherein: The loading amount of the cfDNA sample was approximately 20 ng.
6. The method of claim 1, wherein: The optimal concentration of the primer pair was 600 nM.
7. The method of claim 2, wherein: The optimal concentration of the specific probe is 300 nM, and the optimal concentration of the blocking probe is 100 nM.
8. A kit for detecting ESR1 gene mutation based on cfDNA, characterized in that: The kit comprises a first container and a second container; The first container includes a primer pair specific for ESR1 gene E380Q, whose sequence is shown in SEQ ID NO:76 and SEQ ID NO:83, a primer pair specific for ESR1 gene Y537C, whose sequence is shown in SEQ ID NO:66 and SEQ ID NO:82, a primer pair specific for ESR1 gene Y537N, whose sequence is shown in SEQ ID NO:34 and SEQ ID NO:82, and a primer pair specific for ESR1 gene Y537S, whose sequence is shown in SEQ ID NO:23 and SEQ ID NO:82; The second container includes a primer pair specific for ESR1 gene L536H, whose sequence is shown in SEQ ID NO:45 and SEQ ID NO:82, a primer pair specific for ESR1 gene L536R, whose sequence is shown in SEQ ID NO:57 and SEQ ID NO:82, a primer pair specific for ESR1 gene L536P, whose sequence is shown in SEQ ID NO:19 and SEQ ID NO:82, and a primer pair specific for ESR1 gene D538G, whose sequence is shown in SEQ ID NO:10 and SEQ ID NO:82; The first container and the second container also include specific probes, internal reference probes and internal reference primers that can specifically bind to different sequences of the ESR1 gene, the sequences of the specific probes are shown in SEQ ID NO:85 and SEQ ID NO:86, the two ends of the specific probes are respectively provided with a fluorescent group and a fluorescent quenching group, the sequence of the internal reference probe is shown in SEQ ID NO:87, and the sequence of the internal reference primers are shown in SEQ ID NO:81 and SEQ ID NO:
84.
9. The kit according to claim 8, characterized in that The first container and the second container also include a blocking probe with a sequence as shown in SEQ ID NO: 88, and the blocking probe is used to specifically bind to the non-mutated template in the sample to reduce the probability of the primer binding to the non-mutated template.
10. The kit according to claim 8, characterized in that The first container and the second container also include a probe of the wild sequence of ESR1 as shown in SEQ ID NO:91 and primers of the wild sequence of ESR1 as shown in SEQ ID NO:92 and SEQ ID NO:93, and the probe and primers of the wild sequence are used to estimate the mutation frequency range of ESR1 in the sample.
11. The kit according to claim 8, characterized in that The starting amount of cfDNA samples detected using the kit was 20 ng.
12. The kit according to claim 8 or 9, characterized in that The concentration of the primer pair was 600 nM, the concentration of the specific probe was 300 nM, and the concentration of the blocking probe was 100 nM.
Citation Information
Patent Citations
Detection kit applicable to ESR1 mutation detection
CN107267634A
Hyper-blocking fluorescence quantitative PCR method with high sensitivity for detecting rare mutation
CN108048531A
Multiplex allele specific PCR assays for detection of estrogen receptor ESR1 mutations
CN109790568A
Primer set for detecting mutation of ESR1 gene, reagent, kit and method thereof
CN110452988A
Oligonucleotide group for detecting ESR1 mutant gene, detection method and application
CN117757906A
Cited By
Primer probe set and kit for detecting ESR1 gene mutation and application
CN118531123A
Primer probe set, kit and application for detecting ESR1 gene mutation
CN118531123B
Human ESR1 gene mutation detection kit for breast cancer endocrine resistance treatment guidance
CN119842900A
Primer probe set, method, agent and kit for detecting ESR1 gene mutation on basis of cfdna
WO2026031762A1
